Independent · evidence-anchored·Reviewed by the GLPHelper Medical Team
EN·ES
glp·helper
Find a Provider →
glphelper.com/semaglutide/new-hampshire/manchester
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Manchester, NH

Verified Semaglutide providers in Manchester, NH. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
35
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: New Hampshire
35 of 35 shown

Find a Semaglutide provider in New Hampshire.

Every entry is checked against the NPI registry and the New Hampshire medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by New Hampshire city · /semaglutide/new-hampshire/{city}
Nashua
36 →
§ 03Getting Semaglutide in Manchester
35 providers · Manchester, NH

How to get Semaglutide in Manchester.

35 GLP-1 prescribers and 7 local resource types are on record for Manchester, plus 1 nearby town in the directory.

Prescribers in Manchester
35 prescribers
35 GLP-1 prescribers in Manchester, most listed as Internal Medicine, Endocrinology, Diabetes & Metabolism (13), Family Medicine (13) and Internal Medicine (5). Any New Hampshire-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are Nashua (36 providers).
Around the prescription in Manchester
7 listed nearby
6 dietitians, 2 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Manchester.
Medicaid (weight loss)
Diabetes only
As of April 2026, New Hampshire Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm New Hampshire’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in New Hampshire

Diagnosed diabetes reaches 7.9% of adults in New Hampshire.

of New Hampshire adults have obesity
31.1%
diagnosed diabetes
7.9%

Age-adjusted estimates for New Hampshire, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight losswhat happens after GLP-1s stop
§ 05Support around Semaglutide in Manchester
6 dietitians

The prescription is one part. Here is the rest, in Manchester.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Manchester, NH, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Audrey Anastasia, DrPH, RD, FAND
RD
Registered dietitian
150 Tarrytown Rd
Call 603-622-3162NPI 1063682854
Jeanne Bailey-Clemans
RD
Registered dietitian
100 Mcgregor St
Call 603-663-6032NPI 1487294047
Samantha Bonnier, RDN
RD
Registered dietitian
100 Hitchcock Way
Call 603-695-2500NPI 1346966579
Michelle Boucher, RD
RD
Registered dietitian
39 Brown Hill Rd
Call 603-913-5048NPI 1366023657
Leslie Bullock, MOE, RD
RD
Registered dietitian
195 Mcgregor St Ste 312
Call 603-663-6297NPI 1346511078
Laurie Campbell, RD,LD,CSP,CDE
RD
Registered dietitian · Pediatric
100 Hitchcock Way
Call 603-695-2790NPI 1679589725

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Sandra Bryant, LDN
NUTRITIONIST
Nutritionist
145 Hollis St
Call 603-626-9500NPI 1215566088
Kimberly Lessard, 722447
NUTRITIONIST
Nutritionist · Education
718 Smyth Rd
Call 603-624-4366NPI 1467476309
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in New Hampshire

NPI-verified Semaglutide (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Weight loss doctors in New Hampshire
Board-certified prescribers verified against the NPI registry.
Weight loss clinics in New Hampshire
Clinics running GLP-1 programs, telehealth & in-person.
Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Semaglutide in Alabama→Semaglutide in Alaska→Semaglutide in Arizona→Semaglutide in Arkansas→Semaglutide in California→Semaglutide in Colorado→Semaglutide in Connecticut→Semaglutide in Delaware→Semaglutide in Florida→Semaglutide in Georgia→Semaglutide in Hawaii→Semaglutide in Idaho→Semaglutide in Illinois→Semaglutide in Indiana→Semaglutide in Iowa→Semaglutide in Kansas→Semaglutide in Kentucky→Semaglutide in Louisiana→Semaglutide in Maine→Semaglutide in Maryland→Semaglutide in Massachusetts→Semaglutide in Michigan→Semaglutide in Minnesota→Semaglutide in Mississippi→Semaglutide in Missouri→Semaglutide in Montana→Semaglutide in Nebraska→Semaglutide in Nevada→Semaglutide in New Hampshire→Semaglutide in New Jersey→Semaglutide in New Mexico→Semaglutide in New York→Semaglutide in North Carolina→Semaglutide in North Dakota→Semaglutide in Ohio→Semaglutide in Oklahoma→Semaglutide in Oregon→Semaglutide in Pennsylvania→Semaglutide in Rhode Island→Semaglutide in South Carolina→Semaglutide in South Dakota→Semaglutide in Tennessee→Semaglutide in Texas→Semaglutide in Utah→Semaglutide in Vermont→Semaglutide in Virginia→Semaglutide in Washington→Semaglutide in West Virginia→Semaglutide in Wisconsin→Semaglutide in Wyoming→
Related GLP-1 research
GLP-1s and hair loss
Why rapid loss can shed hair, and what helps it regrow.
how long GLP-1s take to work
When appetite changes show up, and when the weight curve usually follows.
oral and sublingual GLP-1 options
Pills and drops vs injections: what the evidence supports.
§ 09Frequently asked: Semaglutide in New Hampshire

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]